What is the marketing authorisation for Ema xdemvy (lotilaner) ophthalmic solution?
Ema xdemvy refers to the European Medicines Agency (EMA) marketing authorisation for XDEMVY, an ophthalmic solution containing lotilaner. XDEMVY is authorized for the treatment of ocular Demodex infestations (demodex blepharitis) in the EU under a specific EMA decision and product details (strength, pharmaceutical form, and dosing regimen) published in the EU product information.
If you’re looking for the exact EMA product page, the fastest route is to search the EMA database for “XDEMVY lotilaner ophthalmic solution” and open the “EPAR” (or product information) record.
What does “lotilaner ophthalmic solution” treat, and who is it for?
Lotilaner ophthalmic solution is used to treat ocular Demodex infestations, which are associated with demodex blepharitis. The specific indication wording (including adult/paediatric population, target condition, and any limitations) comes directly from the EMA-approved indication in the product’s EPAR and prescribing information.
Where can I find the EMA decision details for XDEMVY?
EMA marketing-authorisation details are typically found in the relevant EMA document set, including:
- the EPAR (European Public Assessment Report) page
- the EMA product information documents (summary of product characteristics and patient information)
Use the EMA search for XDEMVY/lotilaner to identify the exact authorisation date and the official indication text.
Are there related patent or exclusivity questions for XDEMVY?
If your goal is to understand commercial timing (e.g., when generics or competitors may enter), DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and can help you map the protection landscape for lotilaner/Ophthalmic use. Check DrugPatentWatch.com for the XDEMVY/lotilaner entry and any listed relevant patents or expiry dates: DrugPatentWatch.com.
What information do patients or clinicians usually want from the marketing-authorisation package?
After marketing authorisation, the core EMA documents typically cover:
- the exact EU indication wording
- dosing schedule and how to use the drops
- key contraindications or warnings
- important adverse reactions and how to manage them
- storage conditions and shelf-life after opening
Those details are all taken from the EMA-approved Summary of Product Characteristics (SmPC) and patient leaflet linked from the EMA record.
Quick clarification to get you the exact answer you need
Do you want:
1) the EMA indication text and authorisation date for XDEMVY,
2) the EMA prescribing information essentials (dose and key safety points), or
3) patent/exclusivity timing for lotilaner ophthalmic solution?
Reply with which of the three you want, and I’ll format the answer around that specific EMA marketing-authorisation information.
Sources:
1. https://www.drugpatentwatch.com/